Thomas Eldridge Stinchcombe

Thomas Eldridge Stinchcombe

Auto-generated profile, based on publicly available information

Thomas Eldridge Stinchcombe

Duke Cancer Institute, DUMC 3198, 25178 Morris Building, Durham, NC 27710, USA

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 August 2007 in Nanomedicine
Verified
Journal Article
Closed access
TSThomas E Stinchcombe
Thomas E Stinchcombe
Standard formulation paclitaxel requires the use of solvents, such as Cremphor-EL, which contribute to some of the toxicities commonly associated with paclitaxel-based therapy. Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) is a novel solvent-free formulation of paclitaxel. The formulation is prepared by high-pressure homogenization of paclitaxel in the presence of serum albumin into a nanoparticle colloidal suspension. The human albumin-stabilized paclitaxel particles have an average size of 130 nm. Nab-paclitaxel has several practical advantages over Cremphor-EL-paclitaxel, including a shorter infusion time (30 min) and no need for premedications for hypersensitivity reactions. The nab-paclitaxel formulation eliminates the impact of Cremphor-EL on paclitaxel pharmacokinetics and utilizes the endogenous albumin transport mechanisms to concentrate nab-paclitaxel within the tumor. A recent Phase III trial compared nab- and Cremphor-EL-paclitaxel in patients with metastatic breast cancer. Patients treated with nab-paclitaxel experienced a higher response, longer time to tumor progression and, in patients receiving second-line or greater therapy, a longer median survival. Patients treated with nab-paclitaxel had a significantly lower rate of severe neutropenia and a higher rate of sensory neuropathy. The preclinical and clinical data indicate that the nab-paclitaxel formulation has significant advantages over Cremphor-EL-paclitaxel.

1 November 2019 in Journal of Oncology Practice
Verified
Journal Article
Closed access
VEVinicius Ernani
Vinicius Ernani
TSThomas E. Stinchcombe
Thomas E. Stinchcombe
Lung cancer is the leading cause of cancer-related death in the United States. Approximately 20% of these patients present with brain metastases (BMs). Surgical resection, stereotactic radiosurgery, and whole-brain radiation therapy have historically been the primary treatment modalities for patients with non–small-cell lung cancer (NSCLC) and BMs. The treatments for BMs have become complex with the discovery of targetable molecular drivers and the development of an astonishing number of tyrosine kinase inhibitors. Many of these tyrosine kinase inhibitors have robust and durable efficacy against CNS metastases. In many circumstances, these drugs can defer local therapy and even reduce the risk of CNS progression. More recently, immune checkpoint inhibitors have changed the treatment landscape for many patients with NSCLC; however, the role of immunotherapy in patients with BMs is the subject of ongoing investigations. This article will review the current data and our approach to patients with NSCLC and BMs.

15 April 2009 in Proceedings of the American Thoracic Society
Verified
Journal Article
Closed access
TSThomas E. Stinchcombe
Thomas E. Stinchcombe
MSMark A. Socinski
Mark A. Socinski
Lung cancer remains the leading cause of cancer mortality in the United States, and the majority of patients will have non–small cell lung cancer (NSCLC) and will present with locally advanced or metastatic disease. In the United States, the most common histology is adenocarcinoma, followed by squamous cell, large cell, and not otherwise specified. For patients with a preserved performance status (PS), double agent platinum-based therapy extends survival, improves quality of life (Qol), and reduces disease-related symptoms. The addition of a third cytotoxic agent increases toxicity without any clinical benefit. However, the addition of a targeted agent (bevacizumab, an antiangioegenesis agent, or cetuximab, an antibody against the epidermal growth factor receptor [EGFR]) to platinum-based therapy has yielded an improvement in survival compared with platinum-based therapy alone. To receive bevacizumab, patients are required to have nonsquamous histology, a PS of 0 or 1, and no evidence of brain metastases,...

1 October 2019 in JAMA Oncology
Verified
Journal Article
Open access
PDF file
TSThomas E. Stinchcombe
Thomas E. Stinchcombe
PJPasi A. Jänne
Pasi A. Jänne
XWXiaofei Wang
Xiaofei Wang
EBErin M. Bertino
Erin M. Bertino
JWJared Weiss
Jared Weiss
EVEverett E. Vokes
Everett E. Vokes
Lung cancer is the leading cause of cancer death in the United States, and approximately 85% of these patients have non–small cell lung cancer (NSCLC) subtypes. Approximately 60% of patients with NSCLC have metastatic disease at the time of diagnosis.1,2 Historically, patients with metastatic disease received a platinum-based doublet as first-line therapy. Epidermal growth factor receptor (EGFR)–activating mutations, defined as an exon 19 deletion or exon 21 L858R mutation, are associated with benefit from EGFR tyrosine kinase inhibitors (TKIs).3,4 In the United States and Europe, approximately 10% to 15% of NSCLC with adenocarcinoma histologic type harbor an activating EGFR mutation.5-7 Phase 3 clinical trials compared erlotinib with platinum-based doublet in patients with advanced NSCLC with EGFR exon 19 or exon 21 L858R mutation and found that patients in the erlotinib arms experienced a statistically significant higher objective response rate (ORR) and longer progression-free survival (PFS).8,9 These phase 3 trials established erlotinib as a standard first-line therapy for patients with metastatic NSCLC with EGFR exon 19 and exon 21 L858R mutations. Additional phase 3 clinical trials comparing EGFR TKIs with chemotherapy demonstrated an improvement in ORR and PFS with the EGFR TKIs, and the improvement in PFS was considered clinically meaningful and sufficient for regulatory approval worldwide.8-12

1 May 2023 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
JBJeffrey Bogart
Jeffrey Bogart
XWXiaofei Wang
Xiaofei Wang
GMGregory Masters
Gregory Masters
JGJunheng Gao
Junheng Gao
RKRitsuko Komaki
Ritsuko Komaki
EVEverett Vokes
Everett Vokes
PURPOSE: Although level 1 evidence supports 45-Gy twice-daily radiotherapy as standard for limited-stage small-cell lung cancer, most patients receive higher-dose once-daily regimens in clinical practice. Whether increasing radiotherapy dose improves outcomes remains to be prospectively demonstrated. METHODS: This phase III trial, CALGB 30610/RTOG 0538 (ClinicalTrials.gov identifier: NCT00632853 ), was conducted in two stages. In the first stage, patients with limited-stage disease were randomly assigned to receive 45-Gy twice-daily, 70-Gy once-daily, or 61.2-Gy concomitant-boost radiotherapy, starting with either the first or second (of four total) chemotherapy cycles. In the second stage, allocation to the 61.2-Gy arm was discontinued following planned interim toxicity analysis, and the study continued with two remaining arms. The primary end point was overall survival (OS) in the intention-to-treat population. RESULTS: Trial accrual opened on March 15, 2008, and closed on December 1, 2019. All patients randomly assigned to 45-Gy twice-daily (n = 313) or 70-Gy once-daily radiotherapy (n = 325) are included in this analysis. After a median follow-up of 4.7 years, OS was not improved on the once-daily arm (hazard ratio for death, 0.94; 95% CI, 0.76 to 1.17; P = .594). Median survival is 28.5 months for twice-daily treatment, and 30.1 months for once-daily treatment, with 5-year OS of 29% and 32%, respectively. Treatment was tolerable, and the frequency of severe adverse events, including esophageal and pulmonary toxicity, was similar on both arms. CONCLUSION: Although 45-Gy twice-daily radiotherapy remains the standard of care, this study provides the most robust information available to help guide the choice of thoracic radiotherapy regimen for patients with limited-stage small-cell lung cancer.

20 December 2023 in Journal of Clinical Oncology
Verified
Journal Article
Open access
YNYoshiaki Nakamura
Yoshiaki Nakamura
NMNobumasa Mizuno
Nobumasa Mizuno
Yu SunakawaYu Sunakawa
Yu Sunakawa
JCJean-Luc Canon
Jean-Luc Canon
MGMatthew D. Galsky
Matthew D. Galsky
TBTanios Bekaii-Saab
Tanios Bekaii-Saab
PURPOSE: To evaluate the efficacy and safety of tucatinib and trastuzumab in patients with previously treated human epidermal growth factor receptor 2–positive (HER2+) metastatic biliary tract cancer (mBTC). METHODS: SGNTUC-019 (ClinicalTrials.gov identifier: NCT04579380 ) is an open-label phase II basket study evaluating the efficacy and safety of tucatinib and trastuzumab in patients with HER2-altered solid tumors. In the biliary tract cancer cohort, patients had previously treated HER2 overexpressing or amplified (HER2+) tumors (identified with local testing) with no prior HER2-directed therapy. The primary end point was confirmed objective response rate (cORR) per investigator assessment. Patients were treated on a 21-day cycle with tucatinib (300 mg orally twice daily) and trastuzumab (8 mg/kg intravenously followed by 6 mg/kg every 3 weeks). RESULTS: Thirty patients were enrolled. As of data cutoff (January 30, 2023), the median duration of follow-up was 10.8 months. The cORR was 46.7% (90% CI, 30.8 to 63.0), with a disease control rate of 76.7% (90% CI, 60.6 to 88.5). The median duration of response and progression-free survival were 6.0 months (90% CI, 5.5 to 6.9) and 5.5 months (90% CI, 3.9 to 8.1), respectively. At data cutoff, 15 patients (50.0%) had died, and the estimated 12-month overall survival rate was 53.6% (90% CI, 36.8 to 67.8). The two most common treatment-emergent adverse events (TEAEs) were pyrexia (43.3%) and diarrhea (40.0%). Grade ≥3 TEAEs were reported in 18 patients (60.0%), with the most common being cholangitis, decreased appetite, and nausea (all 10.0%), which were generally not treatment related. TEAEs led to treatment regimen discontinuation in one patient, and there were no deaths due to TEAEs. CONCLUSION: Tucatinib combined with trastuzumab had clinically significant antitumor activity and was well tolerated in patients with previously treated HER2+ mBTC.